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Abstract 1 
Background: An elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poor 2 
outcome in various tumors. Its prognostic utility in patients with urothelial carcinoma of the 3 
bladder (UCB) undergoing radical cystectomy (RC) is yet to be fully elucidated.  4 
Methods: A cohort of patients undergoing RC for UCB in a tertiary referral center between 1992 5 
and 2012 was analyzed. NLR was computed using complete blood counts performed pre-RC, or 6 
prior to neo-adjuvant chemotherapy where applicable. Time dependent receiver operating 7 
characteristic curves were used to determine the optimal cut-point for predicting recurrence-free 8 
survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The predictive ability 9 
of NLR was assessed using Kaplan-Meier analyses and multivariable Cox-proportional hazards 10 
models. The likelihood-ratio test was used to determine if multivariable models were improved 11 
by including NLR. 12 
Results: The cohort included 424 patients followed for a median of 58.4 months. An NLR of 3.0 13 
was determined as the optimal cut-off value. Patients with an NLR ≥3.0 had significantly worse 14 
survival outcomes (5y-RFS: 53% vs. 64%, log-rank P=0.013; 5y-CSS: 57% vs. 75%, log-rank 15 
P<0.001; 5y-OS: 43% vs. 64%, log-rank P<0.001). After adjusting for disease-specific 16 
predictors, an NLR ≥3.0 was significantly associated with worse RFS (HR=1.58; 95%CI=1.23-17 
2.05, P<0.001), CSS (HR=1.95; 95%CI=1.43-2.65, P<0.001) and OS (average HR=1.65; 18 
95%CI=1.20-2.29, P<0.001). The likelihood-ratio test confirmed that prognostic models were 19 
improved by including NLR.  20 
Conclusion: NLR is an inexpensive prognostic biomarker for patients undergoing RC for UCB. 21 
It offers pre-treatment prognostic value in addition to established prognosticators, and may be 22 
helpful in guiding treatment decisions. 23 
 3 
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Introduction 1 
Radical cystectomy (RC) with pelvic lymph node dissection is the standard treatment for muscle-2 
invasive (MI) urothelial carcinoma of the bladder (UCB), and is recommended for patients with 3 
non-muscle-invasive (NMI) UCB with high risk of progression (Clark et al, 2013). Despite 4 
curative intent, disease recurs in a significant proportion of patients and 5-year survival rates of 5 
only 40-60% have consistently been reported (Gakis et al, 2013). 6 
 7 
More aggressive treatment options, such as early RC in patients with high-risk NMI UCB or RC 8 
in combination with neo-adjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) have 9 
been shown to improve outcomes (Leow et al, 2013; Meeks et al, 2012; Raj et al, 2011; 10 
Sternberg et al, 2013). However, employing aggressive strategies unselectively to all patients 11 
carries the risk of overtreatment in patients with favorable prognoses. Improved risk-stratification 12 
will individualize the use of such approaches. At this time however, risk stratification based on 13 
clinico-pathological data alone is unlikely to be sufficient for optimal treatment decision-making 14 
(Canter et al, 2011; Ficarra et al, 2005; Shariat et al, 2007). Thus, novel prognostic markers are 15 
needed to improve stratification, and, eventually outcomes, of patients with UCB.  16 
 17 
Inflammation plays an important role in the development and progression of many malignancies 18 
(Grivennikov et al, 2010; Hanahan & Weinberg, 2011). Putative mechanisms include the 19 
increased supply of factors that promote carcinogenesis and tumor progression by cells of the 20 
innate immune systems (i.e. neutrophils) and decreased anti-tumoral response by immune cells of 21 
the adaptive system (i.e. lymphocytes) (Hanahan & Weinberg, 2011). The neutrophil to 22 
lymphocyte ratio (NLR), which can easily be calculated from routine complete blood counts 23 
(CBCs) with differentials, is an emerging marker of host inflammation and has been shown to be 24 
 5 
an independent prognosticator for a variety of solid malignancies (Guthrie et al, 2013; Proctor et 1 
al, 2012; Templeton et al, 2013). However, there is sparse data on the prognostic role of NLR in 2 
patients with UCB (Demirtas et al, 2013; Gondo et al, 2012; Krane et al, 2013). 3 
The objective of our investigation was to evaluate the association between pre-treatment NLR 4 
and survival in patients undergoing RC for UCB in a cohort of patients from a tertiary care 5 
center. 6 7 
 6 
Materials and Methods  1 
Patients and data sources 2 
Using our institutional database, patients who underwent RC between January 1, 1992 and 3 
December 31, 2012 were retrospectively identified. Patients were excluded if CBCs with 4 
differentials were unavailable for analysis (n=14), or if they had a history of conditions that may 5 
have influenced blood cell lines (connective tissue disease: n=4, malignant lymphoma: n=3, 6 
leukemia: n=2, and Human Immunodeficiency Virus (HIV) infection: n=1). Patients undergoing 7 
RC for salvage therapy following failed chemo-radiation (n=20) were excluded due to the 8 
potential influence of prior chemotherapy on blood cell lines. Patients with non-urothelial cancers 9 
(n=9), or for primary prostatic urothelial carcinoma (n=5) were also excluded in order to maintain 10 
a homogenous cohort. Electronic hospital chart review was performed to collect clinical 11 
parameters including blood work results. Mortality data was obtained through the Princess 12 
Margaret Cancer Centre Cancer Registry. Institutional research-ethics board approval was 13 
obtained. 14 
 15 
Primary study exposure 16 
The date of initiation of treatment for each patient was defined as the date of RC, or date of 17 
initiation of NAC for patients who received NAC. All patients were seen for medical assessment 18 
prior to the initiation of treatment. Generally, NLR was calculated using neutrophil and 19 
lymphocyte counts from a routine CBC with differentials done on the same day as these visits 20 
(median of 6 days (interquartile range (IQR): 2-10 days) prior to initiation of treatment). Review 21 
of the pre-treatment clinic notes did not reveal any symptoms or signs of infections that may have 22 
influenced the NLR.  23 
 24 
 7 
Outcomes measures 1 
Patients were generally seen at six to eight weeks after the RC, and otherwise every three to six 2 
months early on for periodic physical exam, imaging to rule out hydronephrosis or tumor 3 
recurrence, and urethroscopy if indicated. Follow up subsequently became less intensive based on 4 
individual physician's practice patterns and clinical suspicion. The outcome measures were 5 
recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS), 6 
measured in months from the date of initial treatment.  7 
 8 
Statistical analysis 9 
Statistical analyses were performed using SAS v9.3 (SAS Institute Inc, Cary, NC, USA). Clinical 10 
characteristics were compared between patients with NLR values above and below the optimal 11 
cut-point (see below) using the Wilcoxon rank-sum test for continuous variables and Pearson’s 12 
Chi-Square test for categorical variables.  13 
 14 
In the literature, there is heterogeneity in the NLR cut-points used (Guthrie et al, 2013). 15 
Therefore, in order to determine the optimal cut-point for clinical use, time-dependent receiver-16 
operating characteristic (ROC) curves were created for each outcome measure at 12, 24, 36, 48, 17 
and 60 months (Heagerty & Zheng, 2005; Lu & Liu, 2006). NLR values between 1.5 and 6.0 18 
were considered in 0.5 increments. The optimal NLR value for each outcome at a given time 19 
point was identified by minimizing the distance from the ROC curve to the top left corner of the 20 
ROC plot (and thus optimizing both sensitivity and specificity) (Perkins & Schisterman, 2006).  21 
 22 
Kaplan-Meier analyses with log-rank tests were then used to compare survival outcomes between 23 
patients with NLR values above versus below the optimal cut-point. To determine how NLR can 24 
 8 
influence risk stratification in the pre-treatment and post-cystectomy settings among patients with 1 
localized disease (without evidence of nodal disease), we performed additional Kaplan-Meier 2 
analyses stratifying by clinical and pathological stage, respectively. In these analyses, patients 3 
receiving NAC or AC were excluded to have a more clear impression of how NLR values impact 4 
the natural history of disease.  5 
 6 
Univariate and multivariable Cox-proportional hazards models were built for each survival 7 
outcome. Multivariable models adjusted for a priori defined patient-related risk factors (age, 8 
gender, Charlson comorbidity index), tumor-related variables (pathological T-stage), treatment-9 
related parameters (year of RC, use of NAC or AC, and surgical margin status), and hematologic 10 
parameters (hemoglobin and platelet counts). AC was operationalized as a time-varying covariate 11 
to address survivor treatment bias (Austin et al, 2006). A robust sandwich covariance matrix 12 
estimator was used to account for clustering of outcomes by surgeon (Lin & Wei, 1989). The 13 
additional value to the models provided by NLR was evaluated using the Likelihood-ratio test to 14 
compare models for each survival outcome with and without NLR. Statistical model assumptions, 15 
including the proportional hazards assumption were tested (Hess, 1995). 16 
 17 
In order to ensure that our use of a cut-point did not introduce bias (Royston et al, 2006), we 18 
performed a sensitivity analysis analyzing NLR as a continuous variable with log-transformation 19 
(due to its skewed distribution). Given that other studies have not included patients receiving 20 
NAC (Gondo et al, 2012), we also performed a sensitivity analysis excluding such patients. All 21 
tests were two-sided with P-values <0.05 considered statistically significant. 22 23 
 9 
Results 1 
The final study cohort consisted of 424 patients with a median follow up of 58.4 months (IQR: 2 
21.3-94.5 months). The cohort characteristics are described in Table 1. Overall, 138 patients 3 
(32.6%) had cancer recurrence and 178 (42.0%) died, of which 110 (25.9%) died of UCB.  4 
  5 
In time-dependent ROC curve analyses, an NLR cut-point of 3.0 minimized the distance from the 6 
ROC curve to the top-left of the plot for 14 out of 15 time points across the three outcome 7 
measures (Supplement Table 1). Given that this cut-point was among those used by other studies 8 
(Guthrie et al, 2013), we proceeded to use this as the optimal cut-point in our study.  9 
 10 
There were 216 (50.9%) patients who had an NLR value ≥3.0 (Table 1). These patients had 11 
significantly lower hemoglobin values, higher platelet counts, and a higher Charlson co-12 
morbidity index, and were less likely to receive AC. They were more likely to have pT3-4 13 
disease (53.9% vs. 38.0%), but there was no significant difference in pN-stage.  14 
 15 
In univariate Kaplan-Meier analyses NLR ≥3.0 versus <3.0 was associated with increased 16 
probability of recurrence (5y-RFS: 53% vs. 64%, log-rank P=0.013, Figure 1a), cancer-specific 17 
mortality (5y-CSS: 57% vs. 75%, log-rank P<0.001, Figure 1b) and overall mortality (5y-OS: 18 
43% vs. 64%, log-rank P<0.001; Figure 1c).  19 
 20 
In univariate Cox models, an NLR ≥3.0 was associated with increased risk of recurrence 21 
(HR=1.53, 95%CI=1.23-1.89, P<0.001, Table 2), cancer-specific mortality (HR=1.88, 22 
95%CI=1.52-2.33, P<0.001, Table 3) and overall mortality (HR=1.80, 95%CI=1.48-2.20, 23 
P<0.001, Table 4).  24 
 10 
Upon adjusting for confounders using multivariable models, NLR remained significantly 1 
associated with increased risk of recurrence (HR=1.58, 95%CI=1.23-2.05, P<0.001, Table 2), 2 
cancer-specific mortality (hazard ratio (HR)=1.95, 95%CI=1.3-2.65, P<0.001, Table 3) and 3 
overall mortality (average HR=1.65; 95%CI=1.20-2.29, P<0.001, Table 4). Of note, the 4 
proportional hazards assumption was satisfied for the models for RFS and CSS, but not for OS. 5 
This would suggest that the HR for the association between NLR and OS is not constant but 6 
varies as a function of time. Therefore the HR presented in Table 4 represents an average value 7 
across the study period. As others have presented such findings(Lipscombe et al, 2013), Figure 2 8 
shows how the HR changes as a function of time from initial treatment (with the corresponding 9 
model that includes an NLR*time interaction term shown in Supplementary Table 2). NLR has 10 
the strongest association with increased risk of overall mortality early on, and then gradually 11 
decreases. This association remained statistically significant up to approximately 50 months from 12 
start of treatment.  13 
 14 
Associations between NLR and increased risk of adverse survival outcomes remained statistically 15 
significant when NLR was analyzed as a log-transformed continuous variable, as well as in the 16 
sensitivity analysis excluding patients who received NAC (data not shown). Using the 17 
Likelihood-ratio test and comparing multivariable Cox-models with and without NLR, it was 18 
determined that NLR significantly improved models for RFS (P=0.013), CSS (P=0.001), and OS 19 
(P=0.003).  20 
 21 
Lastly, we performed exploratory analyses to assess the potential prognostic impact of using 22 
NLR when risk-stratifying patients into two scenarios. For these analyses, patients receiving 23 
NAC or AC were excluded, to better reflect the natural history of disease and avoid confounding 24 
 11 
from adjunctive treatment. The first scenario assessed patients without clinical evidence of nodal 1 
disease (cN0), where risk stratification may guide initial management in the pre-treatment setting. 2 
We sought to determine if NLR further stratified patients beyond their clinical stage, analyzing its 3 
impact in clinically NMI UCB versus MI UCB disease subgroups. In these Kaplan-Meier 4 
analyses (Figure 3a-c), NLR added valuable prognostic information. Patients with clinical NMI 5 
UCB appeared to separate into two groups, with those with clinical NMI UCB and NLR ≥3.0 6 
manifesting survival outcomes comparable to clinical MI UCB. The second scenario was the 7 
post-operative setting among patients who were pN0 (where a decision must be made regarding 8 
the use of AC). NLR further stratified patients within pT-stage categories (Figure 4a-c). Notably 9 
among patients with organ-confined (pT0-pT2) disease, NLR identified a subset of patients who 10 
were at increased risk of adverse oncologic outcomes.11 
 12 
Discussion  1 
The host inflammatory response has gained increasing attention in oncology research. Infiltrating 2 
cells of the immune system are constituents of virtually all neoplasms (Hanahan & Weinberg, 3 
2011). While initially thought to represent an anti-tumoral response, immune cells, particularly 4 
those of the innate immune system, also exhibit effects that promote carcinogenesis and cancer 5 
progression (Grivennikov et al, 2010; Hanahan & Weinberg, 2011). Proposed mechanisms 6 
include increased supply of growth factors, survival factors, pro-angiogenic factors, extracellular 7 
matrix-modifying enzymes (which can facilitate invasion and metastasis), and inductive signals 8 
that may lead to epithelial-to-mesenchymal transition (Hanahan & Weinberg, 2011). Thus, there 9 
is a biological rationale for using NLR, the ratio of circulating neutrophils (immune cells of the 10 
innate system) to lymphocytes (immune cells of the adaptive system), as a measure of the 11 
systemic host response when evaluating the association between inflammation and cancer 12 
outcomes.  13 
 14 
The prognostic role of NLR has been evaluated in numerous epidemiologic studies of various 15 
cancers. Higher NLR has been found to be consistently associated with more advanced stage and 16 
more aggressive tumor behavior (Guthrie et al, 2013; Templeton et al, 2013). However, data 17 
regarding the association of NLR and prognosis for UCB after RC is still scarce. To date, only 18 
three small studies have been published in this population (Demirtas et al, 2013; Gondo et al, 19 
2012; Krane et al, 2013). Gondo and colleagues were the first to describe an association between 20 
higher NLR (> 2.5) and CSS in a cohort of 189 patients undergoing RC (Gondo et al, 2012). 21 
Demirtas and colleagues (201 patients) reported no association between NLR (>2.5) and OS 22 
(Demirtas et al, 2013), whereas Krane and colleagues (68 patients) found that an elevated NLR 23 
(>2.5) was an independent predictor of extravesical disease and worse OS (Krane et al, 2013). In 24 
 13 
the latter study however, ten patients received NAC and it is unclear how their calculated NLR 1 
based on immediate preoperative bloodwork may have been affected.  2 
To the best of our knowledge, our study has the largest sample size investigating the independent 3 
prognostic ability of NLR in patients undergoing RC for UCB. It is the first of its kind to show 4 
that pre-treatment NLR is an independent prognostic factor for RFS, CSS and OS. Among 5 
patients receiving NAC, we used CBCs collected prior to initiation of chemotherapy to eliminate 6 
this potential confounder. In addition, a sensitivity analysis excluding patients receiving NAC 7 
was performed to confirm robustness of the findings.  8 
 9 
There is heterogeneity in reported thresholds used to define an elevated NLR in the literature 10 
(range 2.0 - 7.7) (Templeton et al, 2013). This may reflect variations in the host response for 11 
different disease sites and stages, or may reflect the different approaches used when determining 12 
cut-off values. Not all studies used an accepted method for cut-point determination, and in some 13 
instances the rationale for the cut-point decision was not described (Templeton et al, 2013). All 14 
three previously mentioned studies in the RC population used an optimal NLR cut-point of 2.5 15 
(Demirtas et al, 2013; Gondo et al, 2012; Krane et al, 2013). Gondo and colleagues used the cut-16 
point that generated the lowest p-value in Kaplan-Meier analyses (Gondo et al, 2012). It is 17 
unclear however, if this cut-point was associated with optimal sensitivity and specificity for 18 
adverse oncologic outcomes in their study population. One of the other studies chose 2.5 as their 19 
cut-point for consistency with Gondo and colleagues (Krane et al, 2013), while the third study 20 
did not elaborate on the rationale for their cut-point value (Demirtas et al, 2013).  21 
 22 
We used time-dependent ROC curves to determine the optimal cut-point for NLR. While ROC 23 
curves are conventionally used for binary outcomes to identify points of optimal sensitivity and 24 
 14 
specificity, this approach was adapted for survival analyses (Heagerty & Zheng, 2005; Lu & Liu, 1 
2006). In our study, 3.0 was determined optimal cut-point. We felt it was important to identify an 2 
a priori optimal cut-point both for practical purposes, and to minimize bias. Even so, there is 3 
likely a continuous association between NLR and risk of adverse oncologic outcomes. This 4 
warranted a sensitivity analysis using NLR as a log-transformed continuous variable to ensure we 5 
did not introduce any cut-point bias (Royston et al, 2006). 6 
 7 
Lastly, our exploratory analyses indicate that NLR may better risk-stratify patients in the pre- and 8 
post-operative settings in order to guide treatment strategies. In patients with clinically NMI 9 
UCB, where there is a high risk of under-staging, and a high risk of disease progression to MI 10 
UCB (Chamie et al, 2013; Shariat et al, 2007; Thomas et al, 2012). The NLR may be helpful to 11 
identify patients most likely to benefit from early RC. Similarly, NLR may improve post-12 
operative risk stratification to guide use of adjuvant chemotherapy. However, this was not the 13 
primary objective of this study, and further work is needed to identify the clinical scenarios in 14 
which NLR may be helpful.  15 
 16 
There are limitations to our study. Firstly, this is a retrospective, single-institution observational 17 
study. Secondly, our study included patients across a long recruitment period, during which 18 
practice patterns might have changed. We addressed this by including year of cystectomy in the 19 
multivariable model. Thirdly, we did not measure NLR after RC and therefore cannot investigate 20 
if post-RC improvement of NLR has a predictive value. Finally, we are unable to determine 21 
whether the outcomes following NAC or AC are different among those patients with high vs. low 22 
NLR due to the limited number of patients receiving NAC or AC in our cohort.  23 
 24 
 15 
In conclusion, NLR is an inexpensive hematologic test based on commonly measured parameters 1 
that predicts RFS, CSS and OS in patients with UCB undergoing RC, independent of well-2 
established patient-related and tumor-related predictors. While our results suggest that NLR may 3 
have a role as a prognostic biomarker in the pre-RC and post-RC settings, further studies are 4 
needed to maximize the clinical utility of NLR.  5 
 6 
 7 
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 9 
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Titles and legends to figures 1 
 2 
Figure 1 (a-c): Kaplan-Meier curves for recurrence-free survival (a), cancer specific survival (b), 3 
and overall survival (c) for patients with a neutrophil-to-lymphocyte ratio (NLR) <3 and ≥ 3.  4 
 5 
Figure 2: Instantaneous hazard ratio versus time with corresponding confidence intervals for OS 6 
LCL = Lower 95% confidence limit, UCL = Upper 95% confidence limit.  7 
 8 
Figure 3 (a-c): Kaplan-Meier curves for recurrence-free survival (a), cancer specific survival (b), 9 
and overall survival (c) for patients without clinical evidence of nodal disease (cN0) and 10 
clinically non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer 11 
(MIBC) and a neutrophil-to-lymphocyte ratio (NLR) <3 or ≥ 3, respectively.  12 
 13 
Figure 4 (a-c): Kaplan-Meier curves for recurrence-free survival (a), cancer specific survival (b), 14 
and overall survival (c) for patients with organ-confined bladder cancer (pT0-2 pN0) or non 15 
organ-confined bladder cancer (pT3-4 pN0) and a neutrophil-to-lymphocyte ratio (NLR) <3 or ≥ 16 
3, respectively.  17 
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